Merck & Co Inc
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]
Read More
European markets open lower as Iran war unsettles traders
U.S. President Donald Trump speaks during a roundtable meeting on the administration’s “ratepayer protection pledge” in the Indian Treaty Room at the White House on March 4, 2026 in Washington, DC. Win McNamee | Getty Images LONDON — European stocks were in the red again on Thursday as market participants followed geopolitical developments in the […]
Read More
Russia’s war on Ukraine puts women off having children — and that could spell economic disaster
A woman carries a baby as she reacts after evacuating from Russian troop-occupied Kupiansk town in a bus convoy, amid Russia’s attack on Ukraine, on the outskirts of Kharkiv, Ukraine May 30, 2022. Picture taken May 30, 2022. Ivan Alvarado | Reuters Four years of war between Russia and Ukraine are beginning to take their […]
Read More
Jim Cramer’s top 10 things to watch in the stock market Friday
My top 10 things to watch Friday, Feb. 20 1. Blue Owl Capital’s loan sales, part of a plan to return capital to investors, has observers bringing out “canary in the coal mine” warnings again. While many private credit loans seem mismarked, this situation doesn’t appear tragic in nature. 2. Stock futures were lower after […]
Read More
The White House is launching direct-to-consumer drug site Trump Rx. Here’s what to know
U.S. President Donald Trump makes an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday is slated to announce the launch of TrumpRx – a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs […]
Read More
Jim Cramer says the tech sell-off proves why this old investing rule still matters
The action on Wall Street this week is a reminder of the importance of portfolio diversification, CNBC’s Jim Cramer said Wednesday, as tech-only portfolios have been getting beaten down during the bout of volatility. “Tech’s a good part of the market, it’s just that many of these stocks suddenly aren’t worth as much as we […]
Read More
Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more
Check out the companies making headlines before the bell: Novo Nordisk — The maker of obesity drug Wegovy’s U.S. stock fell about 13% after unexpectedly warning that fiscal 2026 sales will be hurt by lower drug prices in the U.S. even as it anticipates more patients will use its popular GLP-1 drug. Novo Nordisk said […]
Read More
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic […]
Read More
The xAI-SpaceX merger, Palantir earnings, China’s frowning horses and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. I did my workout studio’s Hyrox-themed class yesterday, which not only left me sore but also with a better understanding of what all the hype in the fitness business is about. S&P 500 futures ticked higher this morning. The stock […]
Read More
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more
Check out the companies making headlines before the bell: Palantir — The stock jumped 11% following the AI-powered software provider’s fourth-quarter earnings beat . Palantir reported adjusted earnings of 25 cents per share, versus the 23 cents expected from analysts polled by LSEG. Revenue was $1.41 billion, topping the $1.33 billion consensus estimate. Merck — […]
Read More